Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Predicting the degree of drug-induced QT prolongation and the risk for torsades de pointes.

Ding C.

Heart Rhythm. 2011 Oct;8(10):1535-6. doi: 10.1016/j.hrthm.2011.04.007. Epub 2011 Apr 9. No abstract available.

PMID:
21699823
3.

Dofetilide-induced long QT and torsades de pointes.

Aktas MK, Shah AH, Akiyama T.

Ann Noninvasive Electrocardiol. 2007 Jul;12(3):197-202.

PMID:
17617063
4.

Understanding drug-induced torsades de pointes: a genetic stance.

Kannankeril PJ.

Expert Opin Drug Saf. 2008 May;7(3):231-9. doi: 10.1517/14740338.7.3.231 . Review.

PMID:
18462182
5.

Ibutilide-induced long QT syndrome and torsade de pointes.

Gowda RM, Punukollu G, Khan IA, Patlola RR, Tejani FH, Cosme-Thormann BF, Vasavada BC, Sacchi TJ.

Am J Ther. 2002 Nov-Dec;9(6):527-9.

PMID:
12424513
6.

Early afterdepolarizationlike activity in patients with class IA induced long QT syndrome and torsades de pointes.

Kurita T, Ohe T, Shimizu W, Suyama K, Aihara N, Takaki H, Kamakura S, Shimomura K.

Pacing Clin Electrophysiol. 1997 Mar;20(3 Pt 1):695-705.

PMID:
9080496
7.

What is drug-induced long QT and what is a potential clinical consequence?

Tsiperfal A, Gould M, Thompson C.

Prog Cardiovasc Nurs. 2006 Spring;21(2):104-5. No abstract available.

PMID:
16760695
8.

K201, a multi-channel blocker, inhibits clofilium-induced torsades de pointes and attenuates an increase in repolarization.

Hasumi H, Matsuda R, Shimamoto K, Hata Y, Kaneko N.

Eur J Pharmacol. 2007 Jan 19;555(1):54-60. Epub 2006 Oct 17.

PMID:
17112502
9.

Drug-induced QT prolongation.

Tzivoni D.

Isr Med Assoc J. 2001 Jun;3(6):472. No abstract available.

10.

Torsades de pointes with a severely prolonged QT interval induced by an initial low dose sotalol intake.

Yalta K, Turgut O, Yilmaz A, Yilmaz MB, Kendirlioglu O, Karadas F.

Int J Cardiol. 2007 Apr 4;116(3):e95-7. Epub 2006 Nov 27.

PMID:
17126428
11.

Torsades de pointes and QT prolongation due to a combination of loratadine and amiodarone.

Atar S, Freedberg NA, Antonelli D, Rosenfeld T.

Pacing Clin Electrophysiol. 2003 Mar;26(3):785-6.

PMID:
12698686
12.

Drug-induced QT prolongation and sudden death.

Del Rosario ME, Weachter R, Flaker GC.

Mo Med. 2010 Jan-Feb;107(1):53-8. Review.

PMID:
20222297
13.
14.

Drug-induced QT-interval prolongation and proarrhythmic risk in the treatment of atrial arrhythmias.

Shantsila E, Watson T, Lip GY.

Europace. 2007 Sep;9 Suppl 4:iv37-44. Review.

15.

Taking the "idio" out of "idiosyncratic": predicting torsades de pointes.

Roden DM.

Pacing Clin Electrophysiol. 1998 May;21(5):1029-34. No abstract available.

PMID:
9604234
16.

Sotalol unmasks susceptibility to drug-induced long QT syndrome and torsades de pointes.

Letsas KP, Efremidis M, Sideris A.

Int J Cardiol. 2008 Mar 14;124(3):366-7; author reply 368-9. Epub 2007 Apr 2. No abstract available.

PMID:
17400314
17.

QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone.

Kounas SP, Letsas KP, Sideris A, Efraimidis M, Kardaras F.

Pacing Clin Electrophysiol. 2005 May;28(5):472-3.

PMID:
15869686
18.

Genetic basis of drug-induced arrhythmias.

Vos MA, Paulussen AD.

Ann Med. 2004;36 Suppl 1:35-40. Review.

PMID:
15176422
19.
20.
Items per page

Supplemental Content

Write to the Help Desk